KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Supernus Pharmaceuticals (SUPN) Operating Income: 2010-2024

Historic Operating Income for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Dec 2024 value amounting to $81.7 million.

  • Supernus Pharmaceuticals' Operating Income fell 247.46% to -$60.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$36.9 million, marking a year-over-year decrease of 162.33%. This contributed to the annual value of $81.7 million for FY2024, which is 1649.93% up from last year.
  • As of FY2024, Supernus Pharmaceuticals' Operating Income stood at $81.7 million, which was up 1,649.93% from -$5.3 million recorded in FY2023.
  • Supernus Pharmaceuticals' 5-year Operating Income high stood at $173.7 million for FY2020, and its period low was -$5.3 million during FY2023.
  • Its 3-year average for Operating Income is $40.8 million, with a median of $46.1 million in 2022.
  • Its Operating Income has fluctuated over the past 5 years, first slumped by 111.42% in 2023, then spiked by 1,649.93% in 2024.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Operating Income stood at $173.7 million in 2020, then plummeted by 50.47% to $86.0 million in 2021, then crashed by 46.39% to $46.1 million in 2022, then tumbled by 111.42% to -$5.3 million in 2023, then skyrocketed by 1,649.93% to $81.7 million in 2024.